Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: Current evidence and future directions

Annals of the Rheumatic Diseases

Volumn 75, Issue 8, 2016, Pages 1428-1437

  Schett, Georg ^a   Emery, Paul ^b   Tanaka, Yoshiya ^c   Burmester, Gerd ^d   Pisetsky, David S ^e   Naredo, Esperanza ^f   Fautrel, Bruno ^g   Van Vollenhoven, Ronald ^h  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b CHAPEL ALLERTON HOSPITAL   (United Kingdom)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^g SORBONNE UNIVERSITÉ   (France)

^h Amsterdam Rheumatology and Immunology Center and Reade   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT;

ARTICLE; COMBINATION DRUG THERAPY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG USE; HUMAN; MONOTHERAPY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT DURATION; ARTHRITIS, RHEUMATOID; DISEASE MANAGEMENT; DRUG ADMINISTRATION; EVIDENCE BASED MEDICINE; MEDICAL RESEARCH; PROCEDURES; PROGNOSIS; TRENDS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; BIOMEDICAL RESEARCH; DISEASE MANAGEMENT; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; HUMANS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION;

EID: 84973311826     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-209201     Document Type: Article

References (54)

1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365:2205-19.
2. Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 2016;75:3-15.
3. Aga AB, Lie E, Uhlig T, et al. Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000-2010. Ann Rheum Dis 2015;74:381-8.
4. Albrecht K, Callhoff J, Edelmann E, et al. Clinical remission in rheumatoid arthritis: Data from the early arthritis cohort study CAPEA. Z Rheumatol 2016;75:90-6.
5. Combe B, Rincheval N, Benessiano J, et al. Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort. J Rheumatol 2013;40:1650-7.
6. Landewé RB, Boers M, Verhoeven AC, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-Term structural benefits of a brief intervention. Arthritis Rheum 2002;46:347-56.
7. van Vollenhoven RF, Ernestam S, Geborek P, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 2009;374:459-66.
8. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): A single-blind randomised controlled trial. Lancet 2004;364:263-9.
9. Chatzidionysiou K, van Vollenhoven RF. When to initiate and discontinue biologic treatments for rheumatoid arthritis? J Intern Med 2011;269:614-25.
10. OMahony R, Richards A, Deighton C, et al. Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: A systematic review and meta-Analysis. Ann Rheum Dis 2010;69:1823-6.
11. van den Broek M, Huizinga TW, Dijkmans BA, et al. Drug-free remission: is it already possible? Curr Opin Rheumatol 2011;23:266-72.
12. Yoshida K, Radner H, Mjaavatten MD, et al. Incidence and Predictors of Biological Antirheumatic Drug Discontinuation Attempts among Patients with Rheumatoid Arthritis in Remission: A CORRONA and NinJa Collaborative Cohort Study. J Rheumatol 2015;42:2238-46.
13. Prevoo ML, van t Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
14. Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011;63:573-86.
15. Haschka J, Englbrecht M, Hueber AJ, et al. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping anti-rheumatic therapy: interim results from the prospective randomised controlled RETRO study. Ann Rheum Dis2016;75:45-51.
16. Blanchais A, Berthelot JM, Fontenoy AM, et al. Weekly home self-Assessment of RAPID4/3 scores in rheumatoid arthritis: A 6-month study in 26 patients. Joint Bone Spine 2010;77:582-7.
17. Welsing PM, Landewe R, van Riel PL, et al. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: A longitudinal analysis. Arthritis Rheum 2004;50:2082-93.
18. Hewlett S, Sanderson T, May J, et al. "I am hurting, I want to kill myself": rheumatoid arthritis flare is more than a high joint count-An international patient perspective on flare where medical help is sought. Rheumatology (Oxford) 2012;51:69-76.
19. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
20. Singh JA, Saag KG, Bridges SL, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Ann Rheum Dis 2016;68:1-26.
21. ten Wolde S, Breedveld FC, Hermans J, et al. Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet 1996;347:347-52.
22. Ahern MJ, Hall ND, Case K, et al. D-penicillamine withdrawal in rheumatoid arthritis. Ann Rheum Dis 1984;43:213-17.
23. Tanaka Y, Takeuchi T, Mimori T, et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 2010;69:1286-91.
24. Tanaka Y, Hirata S, Kubo S, et al. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Ann Rheum Dis 2015;74:389-95.
25. Saleem B, Keen H, Goeb V, et al. Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? Ann Rheum Dis 2010;69:1636-42.
26. Brocq O, Millasseau E, Albert C, et al. Effect of discontinuing TNFalpha ntagonist therapy in patients with remission of rheumatoid arthritis. Joint Bone Spine 2009;76:350-5.
27. van der Maas A, Kievit W, van den Bemt BJ, et al. Down-Titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: An observational cohort study. Ann Rheum Dis 2012;71:1849-54.
28. Aguilar-Lozano L, Castillo-Ortiz JD, Vargas-Serafin C, et al. Sustained clinical remission and rate of relapse after tocilizumab withdrawal in patients with rheumatoid arthritis. J Rheumatol 2013;40:1069-73.
29. Nishimoto N, Amano K, Hirabayashi Y, et al. Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study. Mod Rheumatol 2014;24:17-25.
30. van Herwaarden N, Herfkens-Hol S, van der Maas A, et al. Dose reduction of tocilizumab in rheumatoid arthritis patients with low disease activity. Clin Exp Rheumatol 2014;32:390-4.
31. Quinn MA, Conaghan PG, OConnor PJ, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:27-35.
32. Bejarano V, Conaghan PG, Quinn MA, et al. Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis. Rheumatology (Oxford) 2010;49:1971-4.
33. van den Broek M, Klarenbeek NB, Dirven L, et al. Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study. Ann Rheum Dis 2011;70:1389-94.
34. Klarenbeek NB, van der Kooij SM, Göler-Yöksel M, et al. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Ann Rheum Dis 2011;70:315-19.
35. Smolen JS, Emery P, Fleischmann R, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: The randomised controlled OPTIMA trial. Lancet 2014;383:321-32.
36. Detert J, Bastian H, Listing J, et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis 2013;72:844-50.
37. Soubrier M, Puéchal X, Sibilia J, et al. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology (Oxford) 2009;48:1429-34.
38. Nam JL, Villeneuve E, Hensor EMA, et al. Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-To-Target: A double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Ann Rheum Dis 2014;73:75-85.
39. Nam JL, Villeneuve E, Hensor EM, et al. A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: The EMPIRE trial. Ann Rheum Dis 2014;73:1027-36.
40. Emery P, Burmester GR, Bykerk VP, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis 2015;74:19-26.
41. Huizinga TW, Conaghan PG, Martin-Mola E, et al. Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. Ann Rheum Dis 2015;74:35-43.
42. Emery P, Hammoudeh M, FitzGerald O, et al. Sustained remission with tanercept tapering in early rheumatoid arthritis. N Engl J Med 2014;371:1781-92.
43. Fautrel B, Pham T, Alfaiate T, et al. Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study). Ann Rheum Dis 2016;75:59-67.
44. Smolen JS, Nash P, Durez P, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): A randomised controlled trial. Lancet 2013;381:918-29.
45. van Vollenhoven RF, Østergaard M, Leirisalo-Repo M, et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Ann Rheum Dis 2016;75:52-8.
46. van Herwaarden N, van der Maas A, Minten MJ, et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. BMJ 2015 Apr 9;350:h1389.
47. Lamers-Karnebeek FBG, Jacobs H, Fransen J, et al. The Poet-Us Study: Can Ultrasonography Predict Flare in Patients with RA and Persistent Low Disease Activity in Whom the Tnfinhibitor (TNFI) is Stopped? Preliminary Results of an Ongoing Study. Ann Rheum Dis 2013;72:A214.
48. van der Woude D, Young A, Jayakumar K, et al. Prevalence of and predictive factors for sustained disease-modifying anti-rheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum 2009;60: 2262-71.
49. Kavanaugh A, Lee SJ, Curtis JR, et al. Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry. Ann Rheum Dis 2015;74:1150-5.
50. Naredo E, Valor L, De la Torre I, et al. Predictive value of Doppler ultrasound-detected synovitis in relation to failed tapering of biologic therapy in patients with rheumatoid arthritis. Rheumatology 2015;54:1408-14.
51. Iwamoto T, Ikeda K, Hosokawa J, et al. Prediction of relapse after discontinuation of biologic agents by ultrasonographic assessment in patients with rheumatoid arthritis in clinical remission: high predictive values of total gray-scale and power Doppler scores that represent residual synovial inflammation before discontinuation. Arthritis Care Res 2014;66:1576-81.
52. Alivernini S, Peluso G, Fedele AL, et al. Tapering and discontinuation of TNF-α blockers without disease relapse using ultrasonography as a tool to identify patients with rheumatoid arthritis in clinical and histological remission. Arthritis Res Ther 2016;18:39.
53. Tanaka Y, Hirata S. Intensive intervention can lead to a treatment holiday from biological DMARDs in patients with rheumatoid arthritis. Drugs 2014;74:2129-39.
54. Rech J, Hueber AJ, Finzel S, et al. Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment. Ann Rheum Dis 2015.